CN112955432A - 稠合芳香环类衍生物、其制备方法及其在医药上的应用 - Google Patents

稠合芳香环类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN112955432A
CN112955432A CN202080005992.0A CN202080005992A CN112955432A CN 112955432 A CN112955432 A CN 112955432A CN 202080005992 A CN202080005992 A CN 202080005992A CN 112955432 A CN112955432 A CN 112955432A
Authority
CN
China
Prior art keywords
group
compound
alkyl
cycloalkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080005992.0A
Other languages
English (en)
Other versions
CN112955432B (zh
Inventor
张晓敏
张睿
王珏
贺峰
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Chengdu Suncadia Pharmaceuticals Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112955432A publication Critical patent/CN112955432A/zh
Application granted granted Critical
Publication of CN112955432B publication Critical patent/CN112955432B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

涉及稠合芳香环类衍生物、其制备方法及其在医药上的应用。特别地，涉及通式(I)所示的稠合芳香环类衍生物、其制备方法及含有该衍生物的药物组合物，以及其作为ATX抑制剂的用途，和其在制备用于治疗癌症或纤维变性疾病或病症的药物中的用途。其中通式(I)的各取代基同说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (31)

  1. PCT国内申请，权利要求书已公开。
CN202080005992.0A 2019-03-06 2020-03-05 稠合芳香环类衍生物、其制备方法及其在医药上的应用 Active CN112955432B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019101692835 2019-03-06
CN201910169283 2019-03-06
CN2019113748348 2019-12-27
CN201911374834 2019-12-27
PCT/CN2020/077890 WO2020177729A1 (zh) 2019-03-06 2020-03-05 稠合芳香环类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN112955432A true CN112955432A (zh) 2021-06-11
CN112955432B CN112955432B (zh) 2022-11-22

Family

ID=72337609

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080005992.0A Active CN112955432B (zh) 2019-03-06 2020-03-05 稠合芳香环类衍生物、其制备方法及其在医药上的应用

Country Status (3)

Country Link
CN (1) CN112955432B (zh)
TW (1) TW202100512A (zh)
WO (1) WO2020177729A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493453A (zh) * 2020-04-07 2021-10-12 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022007882A1 (zh) * 2020-07-09 2022-01-13 苏州爱科百发生物医药技术有限公司 一种atx抑制剂及其制备方法和应用
WO2022109001A1 (en) 2020-11-18 2022-05-27 Deciphera Pharmaceuticals, Llc Gcn2 and perk kinase inhibitors and methods of use thereof
CN114685487B (zh) * 2020-12-27 2024-04-19 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
TW202334089A (zh) 2021-11-02 2023-09-01 美商夫雷爾醫療公司 Ｐｐａｒｇ反向激動劑及其用途
WO2023093832A1 (zh) * 2021-11-25 2023-06-01 上海济煜医药科技有限公司 三并环衍生物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005652A2 (en) * 1996-08-01 1998-02-12 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL323497A1 (en) * 1995-05-17 1998-03-30 Du Pont Cyclic amides acting as fungicides
EP0836384A1 (en) * 1995-06-20 1998-04-22 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
WO1998023155A1 (en) * 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005652A2 (en) * 1996-08-01 1998-02-12 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493453A (zh) * 2020-04-07 2021-10-12 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用
CN113493453B (zh) * 2020-04-07 2023-06-16 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
WO2020177729A1 (zh) 2020-09-10
TW202100512A (zh) 2021-01-01
CN112955432B (zh) 2022-11-22

Similar Documents

Publication Publication Date Title
CN112955432B (zh) 稠合芳香环类衍生物、其制备方法及其在医药上的应用
JP5654715B1 (ja) テトラヒドロイミダゾ［１，５−ｄ］［１，４］オキサゼピン誘導体（ＴＥＴＲＡＨＹＤＲＯＩＭＩＤＡＺＯ［１，５−ｄ］［１，４］ＯＸＡＺＥＰＩＮＥＤＥＲＩＶＡＴＩＶＥ）
CN104837829B (zh) 抑制剂化合物
CN114846005A (zh) Shp2抑制剂及其应用
WO2021139775A1 (zh) 吡啶酮化合物及应用
US11993585B2 (en) Poly-ADP ribose polymerase (PARP) inhibitors
CN113874354A (zh) 吡啶酮类衍生物、其制备方法及其在医药上的应用
CN110950884B (zh) 含二并环类衍生物抑制剂、其制备方法和应用
CN115279749A (zh) Shp2抑制剂及其组合物和应用
WO2021164746A1 (zh) 取代芳基类化合物
WO2021208918A1 (zh) 作为egfr抑制剂的三环化合物
WO2020182018A1 (zh) 氮杂环化合物、其制备方法及用途
CN110981876B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
WO2020192750A1 (zh) 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
CN114885607B (zh) 喹啉基膦氧化合物及其组合物和用途
WO2021104441A1 (zh) 作为egfr激酶抑制剂的多芳基化合物
CN113493453B (zh) 稠合芳香环类衍生物、其制备方法及其在医药上的应用
CN108779100B (zh) 3,4-二吡啶基吡唑类衍生物、其制备方法及其在医药上的应用
CN112300165A (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
WO2022152259A1 (zh) Cdk2/4/6抑制剂及其制备方法和应用
CN110922408B (zh) 3H-[1,2,3]三唑并[4,5-d]嘧啶-5-胺衍生物及其用途
WO2023232135A1 (zh) Pde4b抑制剂及其用途
CN114591319A (zh) 四氢吡啶并嘧啶类衍生物及其用途
WO2023226976A1 (zh) Sik抑制剂及其组合物、制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20231023

Address after: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee after: SUNCADIA PHARMACEUTICALS Co.,Ltd.

Patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right